Literature DB >> 7948519

Dual skin testing with Mycobacterium avium sensitin and purified protein derivative: an open study of patients with M. avium complex infection or tuberculosis.

C F von Reyn1, P A Green, D McCormick, G A Huitt, B J Marsh, M Magnusson, T W Barber.   

Abstract

The sensitivity and specificity of dual mycobacterial skin testing were assessed in an unblinded study of 22 patients with culture-confirmed Mycobacterium avium complex (MAC) infection and 20 patients with culture-confirmed Mycobacterium tuberculosis infection. Intradermal skin tests were performed with 0.1 mL of M. avium sensitin, 0.1 mL of PPD (purified protein derivative), and two control antigens (mumps and Candida). All patients with M. tuberculosis infection reacted to the skin tests; the mean reaction size was 19.7 +/- 1.4 mm when PPD was administered and 10.3 +/- 1.5 mm when M. avium sensitin was administered. Four patients with MAC were anergic; for the remaining 18, mean reactions of 15.2 +/- 1.4 mm to M. avium sensitin and 4.3 +/- 1.3 to PPD were noted. A skin test was defined as M. avium-dominant or PPD (M. tuberculosis)-dominant if there was a minimum reaction size of > or = 5 mm to the given species, and the reaction to the given species was > or = 3 mm greater than the reaction to the heterologous species. Dominant skin test reactions were present in 18 (90%) of 20 patients with M. tuberculosis and 15 (83%) of 18 nonanergic patients with MAC. The specificity of dominant skin tests was 100% for infection with M. tuberculosis and 100% for infection with MAC. M. avium-dominant skin tests identify subjects with prior MAC infection and distinguish them from patients with M. tuberculosis infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7948519     DOI: 10.1093/clinids/19.1.15

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10.

Authors:  L A van Pinxteren; P Ravn; E M Agger; J Pollock; P Andersen
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

3.  Differential avian and human tuberculin skin testing in non-tuberculous mycobacterial infection.

Authors:  A J Daley; D Isaacs
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

4.  Use of a whole blood assay to evaluate in vitro T cell responses to new leprosy skin test antigens in leprosy patients and healthy subjects.

Authors:  R E Weir; P J Brennan; C R Butlin; H M Dockrell
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

5.  Genetic analysis of Mycobacterium avium complex strains used for producing purified protein derivatives.

Authors:  Makeda Semret; Douwe Bakker; Nonie Smart; Ingrid Olsen; Kaare Haslov; Marcel A Behr
Journal:  Clin Vaccine Immunol       Date:  2006-09

Review 6.  Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections.

Authors:  Jerome A Lindeboom; Lesla E S Bruijnesteijn van Coppenraet; Dick van Soolingen; Jan M Prins; Eduard J Kuijper
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

7.  Real-time PCR assay using fine-needle aspirates and tissue biopsy specimens for rapid diagnosis of mycobacterial lymphadenitis in children.

Authors:  E S Bruijnesteijn Van Coppenraet; J A Lindeboom; J M Prins; M F Peeters; E C J Claas; E J Kuijper
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

8.  Delayed-type hypersensitivity responses to ESAT-6 and MPT64 from Mycobacterium tuberculosis in the guinea pig.

Authors:  M J Elhay; T Oettinger; P Andersen
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

9.  T-cell deficiency and hyperinflammatory monocyte responses associate with Mycobacterium avium complex lung disease.

Authors:  Cecilia S Lindestam Arlehamn; Basilin Benson; Rebecca Kuan; Kimberly A Dill-McFarland; Glenna J Peterson; Sinu Paul; Felicia K Nguyen; Robert H Gilman; Mayuko Saito; Randy Taplitz; Matthew Arentz; Christopher H Goss; Moira L Aitken; David J Horne; Javeed A Shah; Alessandro Sette; Thomas R Hawn
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.